3CLpro of SARS-CoV-2 as a new target for bufadienolides: in silico and in vitro study
Muzaffar KayumovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan. [email protected]Jamoliddin RazzokovDepartment of Biotechnology, Tashkent State Technical University, Universitet 2, Tashkent, 100095, UzbekistanMukhriddin MakhkamovTashkent International University of Education, Imom Bukhoriy 6, Tashkent, 100207, UzbekistanM. O. RadjabovDepartment of Natural Compounds and Applied Chemistry, National University of Uzbekistan, Universitet 4, Tashkent, 100174, UzbekistanNurkhodja MukhamedovDepartment of Natural Compounds and Applied Chemistry, National University of Uzbekistan, Universitet 4, Tashkent, 100174, UzbekistanMakhmudjon KhakimovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, UzbekistanAkmal M. AsrorovAlfraganus University, Yukori Karakamish Str. 2a, Tashkent, 100190, UzbekistanOkhunjon KhasanovDepartment of Medical Biological Sciences, Kimyo International University, Shota Rustaveli 156, Tashkent, 100121, UzbekistanAnsor YashinovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, UzbekistanМ. С. ТашмухамедовInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, UzbekistanAhmidin WaliXinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing Road 40-1, Urumqi, 830011, ChinaAbulimiti YiliXinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing Road 40-1, Urumqi, 830011, ChinaSharafitdin MirzaakhmedovInstitute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, 100125, Uzbekistan
ABI
Аннотация
Аннотация мавжуд эмас.